Multiple Sclerosis Trial, Recruiting NCT06068582 Sponsor: Amsterdam UMC, location VUmc Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Multiple Sclerosis Trial, Recruiting

NCT06068582
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with Multiple Sclerosis (MS) according to a specific set of recognised diagnostic guidelines called the McDonald 2017 criteria
  • People aged between 18 and 67 years old
  • People who have not changed their MS medication in the 3 months before joining the trial (note: medication changes during the trial will be recorded but will not result in removal from the study)
  • People who have not had an MS relapse or taken steroid treatment in the six weeks before their study visits
  • People who show mild memory or thinking difficulties, based on results from a specific cognitive test battery used in MS research (confirm with trial site for exact scoring details)
  • People who are physically able to take part in an exercise program, based on a standard MS disability scale score below a certain level (confirm with trial site)
  • People who are safe to have an MRI scan — meaning no metal implants in the body, not pregnant, and no claustrophobia

Who may not be able to join:

  • People who have a neurological condition other than MS, or a psychiatric disorder
  • People who currently use, or have a history of, drug or alcohol abuse
  • People who are unable to speak or read Dutch
  • People who are currently on sick leave and have been so for 6 weeks or longer
  • People who are currently pregnant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Hanneke E Hulst, Leiden University

Phone: +31 71 5275081

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Amsterdam UMC, location VUmc
Registry
ClinicalTrials.gov
Start date
16 April 2023
Est. completion
1 September 2026

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Quality of Life

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov